The use of intraperitoneal chemotherapy

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• The intraperitoneal (i.p.) route for drug delivery is well-established in theory.
• Extensive data exist on the pharmacology and toxicity of drugs used for ovarian cancer via the i.p. route.
• Specific clinical scenarios exist where i.p. therapy is considered rational.

Purpose of the Study:

• To evaluate the potential of intraperitoneal drug administration in ovarian cancer treatment.
• To highlight the need for rigorous clinical trials to ascertain the efficacy of i.p. therapy.

Main Methods:

• Review of existing pharmacological and toxicological data for i.p. administered drugs in ovarian cancer.
• Identification of clinical situations favoring i.p. therapy.
• Emphasis on the necessity of well-designed clinical trials.

Main Results:

• A strong theoretical foundation supports i.p. drug administration.
• Comprehensive information on i.p. drug properties and safety is available.
• Clinical contexts for rational i.p. use are identified.

Conclusions:

• Intraperitoneal drug administration is a theoretically sound approach for ovarian cancer.
• The primary remaining challenge is to validate its clinical utility through robust trials.
• Further research is essential to determine the definitive role of i.p. therapy.